Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess

Gynecological Endocrinology

Volumn 27, Issue 11, 2011, Pages 935-939

  Lázaro, Iolanda ^a,b   Díaz, Marta ^b,c   Cabré, Anna ^a,b   Masana, Lluís ^a,b   Ibáñez, Lourdes ^b,c  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

FABP4; fat mass; insulin resistance; polycystic ovary syndrome; precocious pubarche

Indexed keywords

ANDROGEN; FATTY ACID BINDING PROTEIN 4; FLUTAMIDE; GLUCOSE; INSULIN; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANDROGEN ANTAGONISTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHILD; CONTRACEPTIVES, ORAL, COMBINED; FATTY ACID-BINDING PROTEINS; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PUBERTY, PRECOCIOUS; TREATMENT OUTCOME;

EID: 80053953090     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.569608     Document Type: Article

References (26)

1. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008;32:1035-1041. (Pubitemid 351986206)
2. Ibáñ ez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide- metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597. (Pubitemid 38507907)
3. Tarkun I, Arslan BC, Cantü rk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin EndocrinolMetab 2004;89:5592-5596. (Pubitemid 39518445)
4. Ibáñ ez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12: 243-252.
5. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli- Labate AM, Cavazza C, Pagotto U, Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;91:3970-3980. (Pubitemid 44536872)
6. Ibáñ ez L, Díaz R, López-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009;10:63-76.
7. Ibáñ ez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol 2001;55: 667-672. (Pubitemid 34204450)
8. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92: 787-796. (Pubitemid 46465641)
9. Ibáñ ez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-29. (Pubitemid 38091417)
10. Ong K, de Zegher F, López-Bermejo A, Dunger DB, Ibáñ ez L. Flutamide-metformin for young post-menarcheal girls with preclinical androgen excess: evidence for differential response by androgen receptor genotype. Eur J Endocrinol 2007;157:661-668. (Pubitemid 350187384)
11. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503. (Pubitemid 351767117)
12. Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007;195: e150-e158. (Pubitemid 47569987)
13. Llaverias G, Noé V, Peñ uelas S, Vázquez-Carrera M, Sánchez RM, Laguna JC, Ciudad CJ, Alegret M. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDLtreated human macrophages. Biochem Biophys Res Commun 2004;318:265-274. (Pubitemid 38526275)
14. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-413.
15. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537-1543. (Pubitemid 46648638)
16. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acidbinding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1796-1802. (Pubitemid 47207176)
17. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, Kim BS. The association of serum adipocyte fatty acidbinding protein with coronary artery disease in Korean adults. Eur J Endocrinol 2009;160:165-172
18. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, et al. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010;211:164-169.
19. Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008;49:1746-1751.
20. Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragonés G, Parra S, Girona J, Masana L. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008;199:147-153. (Pubitemid 351842692)
21. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Sirén J, Hamsten A, Fisher RM, Yki-Järvinen H. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/ macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007;56:2759-2765. (Pubitemid 350044919)
22. Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008;118:2640-2650. (Pubitemid 351949791)
23. Möhlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfü ller B, Arafat AM, Pfeiffer AF, Schöfl C. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol 2007;157:195-200. (Pubitemid 47233124)
24. Ibáñ ez L, López-Bermejo A, Diaz M, Marcos MV, de Zegher F. Metformin treatment for 4 yr to reduce total and visceral fat in low-birthweight girls with precocious pubarche. J Clin Endocrinol Metab 2008;93:1841-1845. (Pubitemid 351656527)
25. Ferrández-Longás A, Mayayo E, Labarta JI, Bagué L, Puga B, Rueda C, Ruiz-Echarri M, Labena C. Estudio longitudinal de crecimiento y desarrollo. Centro Andrea Prader. Zaragoza 1980-2002. In: Garcia-Dihinx J, Romo A, Ferrández A, editors. Patrones de crecimiento y desarrollo en Españ a. Atlas de gráficas y tablas. Madrid: ERGON; 2004. pp 61-115.
26. Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun 2010;393: 89-94.